FineHeart has announced the successful filing of six new international patents for FlowMaker, a fully implantable device for the treatment of patients with advanced heart failure.
These patents increase the company’s international portfolio to 147 within 25 patent families, covering the design, production, surgical implantation of the FlowMaker, the non-contact energy transfer, and the intelligent system for delivering therapy in synergy with each patient’s cardiac rhythm.
The patents bring value and protection to the FlowMaker’s breakthrough technology that, similar to the Pacemaker, is the only cardiac assistance device capable of adapting to the patient’s activity, tracking variations in heart rate, disciminating arrhythmias and permanently synchronising with the heart’s native contraction for optimum synergistic action, the company said in a press release.
Three new US patents, a third headline patent in China, two patents in India and in Japan strengthen FineHeart’s international reputation, particularly in the Asian markets which are highly protective and difficult to access in terms of intellectual and industrial protection, the press release adds. With more than 5 million people with advanced heart failure, and an annual increase of more than 1 million new patients, India is a key future market for minimally invasive surgical solutions, such as those developed by FineHeart, the company stated.
Arnaud Mascarell, CEO and co-founder of FineHeart, said: “These new patents consolidate our position as a leading innovator in implantable medical devices: in the USA, they reinforce the interest in our FlowMaker for the treatment of advanced heart failure. In China, they reaffirm our growing potential in the booming medical device market. We are also very proud of our patent in Japan, where the excellence of our technology is recognised in a fast moving medical device market. In India, the full implantability of FlowMaker represents a major breakthrough and a paradigm shift in cardiology. The technological innovations of the FlowMaker underline our ongoing commitment to improving cardiac care for all patients worldwide.”
